Domestic drug companies in a sweet spot as global players look beyond insulin

Indian drug companies are increasing their presence in the insulin market. They are competing with multinational corporations. Affordable insulin and more type 1 diabetes cases are helping them. Domestic companies accounted for 25% of the market. Multinational companies are shifting focus. This shift creates opportunities for Indian companies. Lupin acquired Huminsulin brand.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/vwOYf2M
via IFTTT